The biotech industry is grappling with a bear market, leading investors to adopt more cautious strategies. Funding has declined significantly, with 2023 being the lowest investment year recently. Focus has shifted from broad, innovative ventures to safer bets like antibody-drug conjugates and platform technologies. Despite challenges, specific areas, particularly novel treatments like oral formulations for weight loss, are still attracting interest. The industry is currently in a phase of recalibration, balancing innovation and risk in a conservative investment climate.
To read more, click here.
[Source: Fierce Biotech, January 16th, 2024]